NEW YORK (GenomeWeb) – Protea Biosciences Group today said that it has signed an agreement to collaborate with the University of Southampton to identify biomarkers that may indicate a risk of developing Alzheimer's disease.

Researchers will use Protea's direct molecular imaging technology and capabilities to study the molecular mechanisms of the aged brain in an effort to identify the markers. Protea researchers, led by Matthew Powell and Greg Kilby, will collaborate with a team of Alzheimer's researchers at the University of Southampton led by Roxana Carare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.